Docebo: The Revenue Miss Is Real, But the 33% Selloff Overcorrected

Docebo reported Q2 2026 results before market open today. The company beat on earnings per share at $0.33 versus the $0.27 consensus, but revenue came in at approximately $64.6 million, missing the $67.1 million analyst estimate — and well below Docebo's own July 17 preliminary guidance range of $68.3–$68.5 million.

The headline read mixed, but the full story is more directional. The stock has fallen 33% over the past 12 months and now trades at 2.1 times trailing revenue and 15 times trailing earnings, generating $44.2 million in free cash flow on a 17.6% margin. That is not a broken business at a bargain-adjacent valuation; that is a company whose valuation reset faster than its fundamentals deteriorated.

The revenue miss matters

Revenue growth was the concern. At $64.6 million, Q2 actuals missed street by roughly 2.5 million, and fell short of the preliminary range the company itself had set three weeks earlier. That signals either an unexpected drag in the second half of the quarter or guidance that was already aspirational. Either way, the gap between what management previewed and what delivered is the number that matters.

Subscription revenue, which represents the recurring core of the business, grew roughly 11% year-over-year based on the preliminary figures (the $63.5–$63.7 million range). Total revenue, including professional services and other streams, shouldered the full miss. Subscription growth is decent but not explosive — the kind of pace that no longer supports the 4–5x revenue multiple this stock commanded during its 2024–2025 peak near $33.

Annual recurring revenue (ARR — the annualized value of all subscription contracts, a leading indicator of future revenue) stood at $255.1 million as of June 30, up 9.5% from $233.1 million a year ago. That figure was dragged down $0.4 million by foreign exchange. Excluding the largest OEM customer (a single-client contract that has been declining in relative weight, now 2.5% of ARR down from 8.4% a year ago), acquisitions, and FX impact, ARR grew approximately 13.9%. That is healthier but still a deceleration from the 20%+ growth that justified the stock's prior valuation.

The customer concentration cleanup is a genuine positive. The OEM deal shrinking from 8.4% to 2.5% of ARR means Docebo is less dependent on a single enterprise relationship. But replacing that concentration with organic growth at only 13.9% ex-OEM is the open question the market is pricing in.

Earnings and cash flow tell a different story

While revenue disappointed, profitability kept pace. EPS of $0.33 beat consensus by about 22%, and the path to that beat comes from disciplined expense management rather than accounting gymnastics. The company's gross margin held at 80%, operating margin sat at 8%, and EBITDA margin reached 9.7% on a trailing basis.

More telling is free cash flow. Docebo generated $44.2 million in trailing-twelve-month FCF, up 61% year-over-year, on a TTM free cash flow margin of 17.6%. Capital expenditures were negligible at under $1 million for the year. That is the cash-generation profile of a mature SaaS business with software-like economics and minimal reinvestment needs — not a growth-at-all-costs company still burning through cash to chase revenue.

The earnings beat paired with strong FCF suggests the revenue miss is not a margin emergency. Cost discipline absorbed the top-line disappointment.

Valuation after the reset

Docebo now trades at a $520 million market cap and $536 million enterprise value. The trailing P/E is 15x; forward P/E is 57x, which reflects the market's skepticism about near-term earnings growth given the revenue slowdown. The stock trades at 2.1x trailing revenue, down from the 5x+ multiples it commanded when it last traded above $28.

The multiple compression is severe, but it has already happened. The stock is down 33% over the rolling year, down 7.7% year-to-date, and currently sits at $20.48 — roughly 38% below its 52-week high of $32.85 and well above its 52-week low of $14.39. The valuation reset is more than 50% off peak enterprise value. That is the kind of multiple destruction that usually overshoots when the underlying business is still generating cash.

For context, Docebo's return on invested capital sits at 52%, and return on equity is 133%. Those are extraordinary numbers for a software company, even a small one. They reflect the asset-light nature of the SaaS model and the heavy share repurchases that have compressed the equity base. Even if revenue growth slows to high single digits, a company with 80% gross margins, 17.6% FCF margins, and 52% ROIC trading at 15x earnings deserves more than a distressed-multiple discount.

The $70 million buyback is not decoration

On July 17, alongside the preliminary Q2 results, Docebo announced a substantial issuer bid — a Canadian mechanism equivalent to a tender offer — to repurchase up to $70 million of shares at $20.40 each. That represents approximately 13.8% of outstanding shares. The buyback is funded from $10 million in cash and a $60 million draw on a credit facility that was recently expanded from $100 million to $150 million.

This is not a cosmetic gesture. At $20.40 per share, the offer price is almost identical to today's market price of $20.48. Management is effectively saying the stock's current trading level does not reflect business value. The funding structure — loading the credit facility rather than draining the balance sheet — is reasonable given the company's FCF generation. Net debt after the buyback would be modest relative to annual cash flow.

Major shareholder Intercap Inc., which owns approximately 63.9% of the company, intends to participate to maintain its ownership percentage. That reduces the effective dilution from the drawdown on the credit facility, since Intercap's participation means fewer shares are actually repurchased from public float. But the signal remains: the largest shareholder and the board consider $20.40 a fair floor.

What breaks the thesis

Three things could go wrong:

• Revenue deceleration deepens. If Q3 guidance ($69.5–$69.7 million total revenue per the July 17 preview) also comes in below expectations, the market will conclude the growth story is structurally impaired, not temporarily soft. At that point, even 15x earnings may not be cheap enough.

• The buyback fails or gets scaled back. If public shareholders don't tender enough shares, or if credit conditions tighten and the $60 million facility draw becomes problematic, the valuation support evaporates. Net debt would rise and the balance sheet would look less flexible.

• FX headwinds intensify. Docebo is a Canadian company with significant international revenue. The $0.4 million ARR drag from foreign exchange in Q2 is small, but a sustained CAD-strength cycle could add up over a full year.

The rating

The revenue miss is real and deserves the attention the market gave it. But the 33% selloff has already compressed the multiple into a zone where the risk/reward resets in favor of the buyer. A company generating 17.6% free cash flow margins, with 80% gross margins, 52% ROIC, and a $70 million buyback anchoring the stock near $20.40, is priced as though its growth story has been permanently impaired.

I'm not convinced of permanent impairment. The ARR growth excluding the declining OEM customer is still roughly 14%. The subscription base is expanding. The earnings beat shows cost discipline. And the valuation is at levels where you're not paying up for perfection — you're getting paid to wait for execution to stabilize.

Rating: Buy. The thesis is that valuation has already absorbed more pain than the business deserves. The next catalyst is Q3 results and whether the $69.5–$69.7 million revenue guidance holds. If it does, this stock has a clear path back toward the mid-$20s. If it doesn't, the buyback and free cash flow provide a floor that makes the downside at current levels limited.